Praxis Precision Medicines Stock Fundamentals
PRAX Stock  USD 71.87 0.86 1.18% 
Praxis Precision Medicines fundamentals help investors to digest information that contributes to Praxis Precision's financial success or failures. It also enables traders to predict the movement of Praxis Stock. The fundamental analysis module provides a way to measure Praxis Precision's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Praxis Precision stock.
At this time, Praxis Precision's Interest Expense is fairly stable compared to the past year. Reconciled Depreciation is likely to rise to about 447.3 K in 2024, despite the fact that Tax Provision is likely to grow to (4.3 K). Praxis  Select Account or Indicator 
Praxis Precision Medicines Company Return On Equity Analysis
Praxis Precision's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Praxis Precision Return On Equity  0.47 
Most of Praxis Precision's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Praxis Precision Medicines is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition 
Praxis Total Stockholder Equity
Total Stockholder Equity 

Based on the latest financial disclosure, Praxis Precision Medicines has a Return On Equity of 0.4716. This is 98.03% lower than that of the Biotechnology sector and 98.71% lower than that of the Health Care industry. The return on equity for all United States stocks is 52.13% higher than that of the company.
Praxis Precision Med Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Praxis Precision's current stock value. Our valuation model uses many indicators to compare Praxis Precision value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Praxis Precision competition to find correlations between indicators driving Praxis Precision's intrinsic value. More Info.Praxis Precision Medicines is regarded second in return on equity category among its peers. It is regarded third in return on asset category among its peers . At this time, Praxis Precision's Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the pricetoearnings (P/E), pricetobook (P/B), pricetosales (P/S), pricetocash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Praxis Precision's earnings, one of the primary drivers of an investment's value.Praxis Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Praxis Precision's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Praxis Precision could also be used in its relative valuation, which is a method of valuing Praxis Precision by comparing valuation metrics of similar companies.Praxis Precision is currently under evaluation in return on equity category among its peers.
Praxis Precision ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower socialengagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Praxis Precision's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Praxis Precision's managers, analysts, and investors.Environmental  Governance  Social 
Praxis Fundamentals
Return On Equity  0.47  
Return On Asset  0.29  
Operating Margin  (105.01) %  
Current Valuation  941.54 M  
Shares Outstanding  17.76 M  
Shares Owned By Insiders  0.20 %  
Shares Owned By Institutions  99.80 %  
Number Of Shares Shorted  1.72 M  
Price To Book  3.08 X  
Price To Sales  729.23 X  
Revenue  2.45 M  
EBITDA  (125.94 M)  
Net Income  (123.28 M)  
Cash And Equivalents  165.4 M  
Cash Per Share  3.70 X  
Total Debt  2.5 M  
Debt To Equity  0.03 %  
Current Ratio  4.56 X  
Book Value Per Share  23.60 X  
Cash Flow From Operations  (111.14 M)  
Short Ratio  5.84 X  
Earnings Per Share  (5.59) X  
Price To Earnings To Growth  0.03 X  
Target Price  148.67  
Number Of Employees  82  
Beta  2.74  
Market Capitalization  1.29 B  
Total Asset  87.95 M  
Retained Earnings  (653.92 M)  
Working Capital  69.13 M  
Net Asset  87.95 M 
About Praxis Precision Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Praxis Precision Medicines's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Praxis Precision using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Praxis Precision Medicines based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Last Reported  Projected for Next Year  
Current Deferred Revenue  1.4 M  2.6 M  
Total Revenue  2.4 M  2.6 M  
Cost Of Revenue  432 K  739.5 K  
Stock Based Compensation To Revenue  9.14  8.13  
Sales General And Administrative To Revenue  15.47  13.75  
Research And Ddevelopement To Revenue  31.91  28.37  
Capex To Revenue  0.02  0.02  
Revenue Per Share  0.33  0.30  
Ebit Per Revenue  (46.48)  (48.80) 
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a marketneutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Praxis Stock Analysis
When running Praxis Precision's price analysis, check to measure Praxis Precision's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Praxis Precision is operating at the current time. Most of Praxis Precision's value examination focuses on studying past and present price action to predict the probability of Praxis Precision's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Praxis Precision's price. Additionally, you may evaluate how the addition of Praxis Precision to your portfolios can decrease your overall portfolio volatility.